Tiny trial aims to shed light on PSMA scans in hard-to-treat prostate cancer
NCT ID NCT04925648
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tested whether taking dasatinib alone or with darolutamide for 14 days can increase PSMA levels on PET scans in men with metastatic prostate cancer. Only 4 men participated, all with low PSMA uptake on their initial scan. The goal was to learn more about how PSMA expression works, not to treat the cancer directly.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for METASTATIC PROSTATE CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Kinghorn Cancer Centre, St. Vincent's Hospital
Sydney, New South Wales, 2010, Australia
-
Peter MacCallum Cancer Centre
Melbourne, Victoria, 3000, Australia
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Chemo combo vs. radioactive drug: which tames aggressive prostate cancer?
- Can a blood filtering technique reveal more about prostate cancer spread?
- Can a vaccine plus immune booster tackle resistant prostate cancer?
- Can a smart drug deliver a toxic payload to prostate cancer cells?
- Can a blast of testosterone shrink hard-to-treat prostate cancer?
- A PET scan and a blood test may predict which men with advanced prostate cancer will benefit from targeted therapy